1. 1 HAI conference 18-11-2004 Medicines for Europe and the World Setting priorities: missing the point A rational medicines policy for Europe A rational medicines policy for Europe Ron Hendriks, AIM President

2. AIM in the world (www.aim-mutual.org)

3. AIM common values Access to quality health care Solidarity Selfgovernance Social profit

4. Association Internationale de la Mutualité 4 AIM supports the creation of public health needs based R&D agenda Priority : Prevention Health education Living and working conditions Dutch initiative on priority medicines

5. Association Internationale de la Mutualité 5 Price control systems: unpredictable ? they do not know how long it will take for a decision, what the final price will be and whether additional information or studies will be required…this results in an unpredictable lottery for companies who have brought a product to market through a series of regulatory hurdles and still do not know what the final reimbursed price will be. WHO report Chapter on innovation

6. Association Internationale de la Mutualité 6 Barriers to innovation in pharmaceutical R&D importance of comparative trials (1) private insurers and the government would set aside some fraction of their annual medicines spending to endow a new institute to provide an independent source of reputable research into comparative effectiveness and cost. WHO report Chapter on innovation

7. Association Internationale de la Mutualité 7 Barriers to innovation in pharmaceutical R&D importance of comparative trials (2) electronic prescription and medical databases to conduct Phase IV and/or pharmaco-epidemiologic studies in place of randomized, controlled, comparative clinical trials. The European Commission is presently discussing so-called e-prescribing and other information technology (IT) approaches as part of their interest in the information WHO report Chapter on innovation

8. Association Internationale de la Mutualité 8 AIM priority concerns: Non pharmaceutical prevention and health education Relative effectiveness: added therapeutic value Comparative and long-term trials Reflection on rewarding break-through innovation Rational use Permanent independent training of doctors Improved transparency and access to information Conclusions